Fig. 5: In vivo antitumor performance.
From: Optically tunable catalytic cancer therapy using enzyme-like chiral plasmonic nanoparticles
a Schematic illustration of in vivo experiments with CT26 tumor-bearing mice (created in BioRender, https://Biorender.com/t51f293). b Tumor suppression profiles of the control group (PBS-treated) and sample treated groups under different light irradiation conditions (n = 4 mice per group). Statistical analysis was conducted by one-way ANOVA test (**p < 0.01, ***p < 0.001). c Body weight change profiles of the control group (PBS-treated) and sample treated groups under different light irradiation conditions (n = 4 mice per group). d Weight of the dissected tumors of the control group (PBS-treated) and sample treated groups under different light irradiation conditions on day 18. (n = 4 mice per group). Statistical analysis was conducted by one-way ANOVA test (****p < 0.000). Inset: corresponding tumor photograph. scale bar = 1 cm. Histochemical analyses of (e) H&E and (f) TUNEL of tumor tissues harvested from control group (PBS-treated) and sample treated groups under different light irradiation. g TUNEL positive fluorescence intensity of tumor sections with control group (PBS-treated) and sample treated groups under different light irradiation. (n = 3 independent experiments). Statistical analysis was conducted by one-way ANOVA test (*p < 0.1,**p < 0.01, ***p < 0.001, ****p < 0.0001). h Blood biochemical analysis of CT26 tumor-bearing mice after different conditions of CPL irradiation in the presence of D-Au and L-AuPd. The Dark group was not irradiated with CPL in the presence of D-Au and L-AuPd. The control group was treated with PBS. Source data are provided as a Source Data file.
